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Abstract
Tremendous gains have been made in the prevention of mother-to-child HIV transmission 
(PMTCT) in sub-Saharan Africa. Ambitious goals for the “virtual elimination” of pediatric HIV 
appear increasingly feasible, driven by new scientific advances, forward-thinking health policy, 
and substantial donor investment. To fulfill this promise, however, rapid and effective 
implementation of evidence-based practices must be brought to scale across a diversity of settings. 
The discipline of implementation research can facilitate this translation from policy into practice; 
however, to date, its core principles and frameworks have been inconsistently applied in the field. 
We reviewed the recent developments in implementation research across each of the four “prongs” 
of a comprehensive PMTCT approach. While significant progress continues to be made, a greater 
emphasis on context, fidelity, and scalability – in the design and dissemination of study results – 
would greatly enhance current efforts and provide the necessary foundation for future evidence-
based programs.
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Considerable advances have been made to prevent mother-to-child transmission of HIV 
(PMTCT). Unlike in North America and Europe, where vertical transmission of HIV is now 
exceedingly low, progress has lagged in sub-Saharan Africa due to numerous contextual 
factors. However, new developments in clinical research, policy, and program expansion 
have led to a renewed hope about the dramatic reduction of pediatric AIDS. Numerous 
clinical trials, for example, have demonstrated the efficacy of maternal antiretroviral therapy 
(ART) through pregnancy, delivery, and breastfeeding [1]. The World Health Organization 
and other international donors have strongly endorsed the “Option B+” strategy to provide 
lifelong ART to all HIV-infected pregnant and breastfeeding women [2], a policy that seeks 
to reduce key bottlenecks by making treatment universal. Joint investments in PMTCT – 
from international donors and local governments – have made considerable resources 
available to “virtually eliminate” pediatric AIDS and reduce maternal deaths worldwide [3, 
4].
Over the past decade, there has been growing recognition that scientific discovery and 
translational research alone will not result in the public health gains sought by local 
governments and international agencies [5]. For any particular health problem, there may 
exist a number of proven clinical interventions; however, their potential is often unrealized 
because of poor implementation, poor access through health systems, and incomplete uptake 
by health systems, care providers, or individuals in need [6]. To address this gap, the field of 
implementation research has emerged as a priority area. This is certainly true in the field of 
HIV, where greater efforts have been made to articulate and address the “know-do” gap 
across prevention, care, and treatment [7–9]. Despite its growing prominence, however, the 
approaches and frameworks of implementation research are often misunderstood outside of 
the discipline [10]; as a result, concerted efforts have been made to better define and 
disseminate its foundational principles [11**, 12]. The traditional view of research has been 
linear, with strong emphasis on discovery and translation. More recent efforts have recast 
this paradigm as cyclical, with bidirectional interplay between each phase. Key steps have 
been articulated beyond the “translational” clinical trials that support development of 
applied clinical interventions (T2): implementation strategies designed to optimize uptake of 
guidelines and clinical interventions (T3) and measurement of the resulting population 
impact (T4) [11**].
In this report, we reviewed published articles and conference abstracts in the medical 
literature focused on PMTCT implementation research over the past three years. We framed 
our discussion according to the four “prongs” of PMTCT articulated by the United Nations: 
(1) primary prevention of HIV among women of childbearing age, (2) prevention of 
unintended pregnancies among HIV-infected women, (3) prevention of mother-to-child 
transmission among HIV-infected women, and (4) linkage of HIV-infected women and 
children to long-term HIV care and treatment.
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Preventing incident HIV infection among women of childbearing age
Significant advances have been made in the area of HIV prevention over the past decade. 
There now exists a growing body of evidence that biomedical and behavioral interventions 
used in combination can dramatically reduce incident HIV infection at a population level. A 
number of review articles have been published over the past several years, which together 
provide a comprehensive survey of the field [13–15]. Here, we emphasize three areas of 
particular relevance to women of childbearing age.
Pregnancy and breastfeeding are windows of elevated risk for maternal HIV acquisition. 
Drake and colleagues showed that the overall incidence during pregnancy/postpartum was 
3.8/100 person-years (95%CI: 3.0–4.6) in a recent meta-analysis, with higher rates during 
pregnancy (4.7/100 person-years) than afterwards (2.9/100 person-years; p=0.18). Perhaps 
most relevant to this review are the high mother-to-child transmission rates observed among 
incident cases during pregnancy. Pooled transmission rates were estimated at nearly 23%, at 
rates two- to threefold higher than those observed with chronic HIV infection [16*]. 
Tailored prevention interventions are needed for this population, ones that incorporate both 
biomedical and behavioral components. Partner HIV testing, for example, can help to 
identify serodiscordant couples that may be eligible for intensive counseling and “treatment 
for prevention” modalities. Pre-exposure prophylaxis during the pregnancy/breastfeeding 
period may also be promising, though the risks and benefits of antiretroviral drug exposure 
to otherwise healthy HIV-uninfected mother-infant pairs must be carefully weighed [17].
Controversy persists regarding the association between hormonal contraception and HIV 
acquisition. A pair of recently published meta-analyses – conducted by Ralph et al [18] and 
Morrison et al [19] – contribute meaningfully to the ongoing debate. In these studies, depot-
medroxyprogesterone acetate was associated with elevated risk for HIV acquisition (hazard 
ratios of 1.40 [95%CI: 1.16–1.69] and 1.50 [95%CI: 1.24–1.83], respectively); however, 
similar associations were not observed with other forms of hormonal contraception (i.e., 
combination oral contraceptives, neorethisterone enanthate). Given the widespread use of 
depot-medroxyprogesterone acetate, there is also need to weigh these risks against the 
broader benefits in maternal health and mother-to-child HIV transmission [20]. The 
potential for residual confounding in these analyses is an ongoing concern, particularly 
given the potential for misclassification around exposure status [21]. A large randomized 
trial is currently planned and should provide important insight to this complex public health 
issue [22].
Adolescence is a period of elevated risk for HIV acquisition, particularly for girls, and this 
has been an area of increased emphasis in programs and research. While many studies have 
focused on engagement into care [23, 24], including the positive impact of parent 
involvement [25], broader approaches are needed to address the behavioral, social, and 
environmental complexities individuals face during this transitional period [26, 27]. 
Structural interventions may hold promise. Epidemiologic data from the Rakai Community 
Cohort Study demonstrated significant declines in HIV incidence and reported HIV risk 
behaviors from 1999 to 2011, encouraging trends that coincided with increases in school 
enrollment and decline in adolescent marriage, among other factors [28]. The “SHAZ!” 
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(Shaping the Health of Adolescents in Zimbabwe) trial, for example, provided feasibility 
data about a combination package that included life-skills and health education, vocational 
training, micro-grants, and social support. The pilot intervention was effective in modifying 
risk-related behaviors, including lower risk for transactional sex, higher likelihood of using a 
condom, and fewer unintended pregnancies [29]. The HIV Prevention Trials Network 
(HPTN) Protocol 068 is examining the impact of conditional cash transfers for school 
attendance on HIV incidence among adolescent girls in South Africa. One of the largest of 
its kind, this study is currently in follow-up, with primary results are anticipated in the 
coming year.
Preventing unintended pregnancies among HIV-infected women
Prevention of unintended pregnancies among HIV-infected women is a core component to 
PMTCT efforts globally; however, unmet need for contraception in sub-Saharan Africa 
remains high [30]. In most settings, this gap reflects a misalignment of patient needs and 
available services, which can in turn translate into poor uptake of and adherence to family 
planning services. Several recent studies demonstrate how increased patient engagement 
may lead to higher utilization rates. In cohort of HIV-serodiscordant and -seroconcordant 
couples from Zambia and Rwanda, fertility goal-based counseling resulted in significant 
increases in uptake for intrauterine device and hormonal implants [31]. Similarly, 
participation in video-based intervention describing family planning methods was associated 
with decreased incident pregnancy rates, with lower rates observed among women already 
on contraception [32]. Multiple studies have shown the important association between 
partner opinion and contraceptive use [33–36], highlighting a role for active male 
engagement within effective family planning services. In South Africa, researchers also 
demonstrated higher rates of contraception use as women advanced further along the HIV 
treatment cascade, a marker of healthcare engagement. Reported use increased from less 
than 40% among HIV-infected women who did not yet know their status to over 70% 
among women who were already on ART for several years [37].
While interventions to increase patient-provider interaction may generate demand for family 
planning, in order to increase uptake, this demand must be met with adequate supply. The 
availability and accessibility of family planning services are thus critical. Integration of 
family planning services, within the context of PMTCT or HIV care, has been studied in 
different settings. Most rigorous has been an 18-site cluster-randomized trial in the Nyanza 
Province of Kenya. Women seen at integrated sites were more likely to use more effective 
contraceptive methods (OR: 1.81, 95%CI: 1.24–2.63) but less likely to use condoms (OR: 
0.64, 95%CI: 0.35–1.19), though this latter finding was not significant. Pregnancy rates at 
one year did not differ between the two study arms (OR: 0.90; 95%CI: 0.68–1.20) but, as the 
authors note, the time was likely insufficient for this outcome [38*]. Community-based 
approaches for contraception can also extend the reach of traditional facility-based services. 
Numerous programs have integrated trained community workers into the health workforce, 
allowing them to distribute oral contraceptive pills and condoms and administer injections 
[39]. Community pharmacies and drug distribution points could also decongest busy clinics 
and promote long-term adherence [40]. Even with expanded access, however, it is important 
to acknowledge the role of the underlying health system for provision of quality family 
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planning services. Targeted implementation strategies to improve supply chain, health 
infrastructure, or human resources are urgently needed in many African settings.
Preventing mother-to-child transmission of HIV
First developed and implemented in Malawi [41], the so-called Option B+ strategy to 
provide universal lifelong ART to pregnant and breastfeeding women has now been adopted 
in many African countries [42]. A key rationale for Option B+ among policymakers has 
been the simplification of PMTCT strategies and better alignment to adult treatment 
guidelines [43]. Formative work by Ngarina, et al. suggests that patients share similar 
preferences. In qualitative interviews and focus group discussions of Tanzanian mothers, 
universal maternal ART was preferred over daily continuous infant nevirapine prophylaxis 
during breastfeeding because of the potential for reduced stigma and enhanced adherence 
[44]. As combination antiretroviral regimens become the sole standard of care for PMTCT 
in many settings, however, there may be unanticipated consequences to this streamlined 
public health approach. Researchers have identified a significant proportion – up to 15% in 
some studies [45] – who decline maternal combination regimens outright; another group 
silently defaults from care [46]. Without viable alternatives, these women may not receive 
any antiretroviral interventions to reduce HIV transmission to their infants. In Botswana, 
researchers found a significant increase in ART uptake following the introduction of 
universal maternal combination regimens for PMTCT (adjusted odds ratio [OR]: 2.59, 
95%CI: 2.25–2.98), but this was accompanied by a twofold for receiving no PMTCT 
intervention at all (adjusted OR: 2.10, 95%CI: 1.74–2.53). The net result was a projected 
increase in mother-to-child transmission at 6 months of age at the population level, from 
3.8% to 4.7% [47].
The rapid adoption of Option B+ into policy has presented unique implementation 
challenges. Because its introduction has been relatively recent, few published studies to date 
have examined the contextual issues (e.g., health infrastructure, community characteristics, 
stigma) related directly to the strategy. Nevertheless, lessons can be adopted from the 
broader PMTCT literature. Despite significant investments in community-based HIV 
education and sensitization, for example, stigma persists. A systematic review by Gourlay 
and colleagues highlighted the critical role of stigma and fear of status disclosure as major 
barriers to health-seeking behaviors for PMTCT [48**]. Work by Kohler, et al. 
demonstrated the high levels of stigma and discrimination in Kenya, with most HIV-positive 
women (89%) reporting blame or judgment of people with HIV. Feelings of shame were 
significantly associated with decreased likelihood of maternal HIV testing, completing 
courses of antiretroviral prophylaxis, and infant HIV testing [49]. In Tanzania, patients 
reported a lack of supportive communication around PMTCT and, for some, healthcare 
providers were viewed as potentially breaching confidentiality around HIV status [50]. 
Interventions designed to address these problems – and their community perceptions – are 
needed to improve uptake of PMTCT services.
Research on supply-side interventions provides additional insight. Several themes emerge 
from the recent medical literature. A holistic view of the PMTCT continuum of care is 
needed in order to realize the full potential of Option B+ at a population level. While there 
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has been great emphasis on the initiation of and adherence to ART, earlier steps in the 
“PMTCT cascade” – e.g., entry into antenatal care, consent to HIV testing – can also have 
significant downstream impact on reducing pediatric HIV [51]. For example, although 
pregnancy is increasingly recognized as a high-risk period for HIV acquisition [16], repeat 
maternal HIV testing to identify new infections during pregnancy and breastfeeding 
continues to be overlooked [52, 53].
Alternate entry points are needed outside of traditional facility-based services for PMTCT. 
In a randomized study of home- versus facility-based HIV testing, couples allocated to the 
home visit arm were more likely to test for HIV together (85% vs. 36%, p<0.001); in 
addition, more HIV-seropositive men (12% vs. 8%, p=0.25) and more HIV-discordant 
couples (15% vs. 5%, p=0.003) were identified through the home-based strategy [54*]. 
Similarly, the cluster-randomized “Goodstart” study showed positive outcomes with 
structured community-based support during pregnancy and breastfeeding. At 12 weeks of 
age, women in the intervention arm reported higher rates of exclusive breastfeeding and 
increased infant weight and length for age z-scores, but HIV-free survival (a primary 
outcome) did not differ significantly between groups [55]. Entry into PMTCT from novel 
venues such as church congregations are encouraging and currently under study [56].
Task-shifting strategies hold promise, particularly where human resources are limited, but 
their overall public health benefit may depend on the extent to which they can be 
implemented. In one study in Malawi, trained traditional birth attendants referred nearly all 
HIV-infected patients to health centers; however, the patient transportation to the health 
center and provider tracking of referrals were persistent challenges [57]. Similar work in 
rural Mozambique demonstrated increases in referral to health facilities when traditional 
healers underwent a structured educational intervention; however, the overall rates remained 
low [58]. In South Africa's Free State, a 32-facility cluster-randomized studied the impact of 
lay health worker support at the facility level, which included health promotion sessions, 
one-one-meetings to promote HIV testing and linkages to care, and targeted HIV education. 
The intervention was not associated with improved PMTCT uptake across most indicators, 
except for antenatal HIV retesting at 32 weeks gestation, where a modest but significant 
increase was observed (adjusted OR: 1.34, 95%CI: 1.01–1.77) [59].
While efforts have been made to understand the population impact of PMTCT services [60–
62], their translation into practical interventions for frontline providers has been more 
limited. Gimbel and colleagues designed a simple, Excel-based spreadsheet to reconstruct 
the PMTCT cascade at the facility level, using commonly collected program indicators [63]. 
Integration of this tool into ongoing monitoring and evaluation activities could result in 
tailored, context-specific responses to local challenges. Similarly, formal quality 
improvement approaches could provide a structured framework for targeted interventions. 
Several pilot studies have been conducted in PMTCT to date [64, 65]; a larger cluster-
randomized trial in Kenya, Mozambique, and Cote d'Ivoire is currently studying this very 
question [66].
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Linking HIV-infected women to long-term care
By simplifying the criteria for ART eligibility, the Option B+ approach reduces bottlenecks 
for treatment initiation. While the absolute numbers of women initiating ART have 
increased, there remain considerable challenges for short- and long-term retention in care. 
Nearly one-fifth (17%) of women initiating Option B+ in Malawi had become lost to follow-
up (LTFU) by 6 months on treatment, with significant heterogeneity between sites. When 
compared to women who started ART because of low CD4 counts and/or advanced clinical 
staging, those who started therapy during pregnancy were five times more likely to never 
return following their initial visit (OR: 5.0, 95%CI: 4.2–6.1) [67]. In a retrospective cohort 
from Cape Town, South Africa, approximately one-third of women who initiated ART 
during pregnancy had disengaged from care in the 6 months following delivery, with higher 
rates observed in the postpartum period than in pregnancy (6.2 vs. 2.4 per 100 woman-
months, p<0.0001) [68]. In separate qualitative studies, commonly reported reasons for 
stopping ART included travel, cost of transportation, conflicts with work commitments, 
negative treatment from health providers, and stigma [46, 69].
Poor long-term adherence and retention can threaten the expected maternal health benefits 
of Option B+. Women who prematurely interrupt lifelong treatment risk viral rebound and 
disease progression; poor adherence may select for drug resistant HIV variants, which can 
later comprise treatment when ART is re-initiated. In addition, a purported benefit of Option 
B+ is the decreased risk for mother-to-child transmission in future pregnancies, since the 
initiation of ART prior to conception should lead to prolonged viral suppression. In a cross-
sectional study of pregnant South African women, however, nearly one-quarter who 
reported initiated ART prior to conception had detectable viremia at first antenatal visit [70].
Several have sought to better understand the impact of health delivery on patient retention in 
care. In one novel study, von Lettow and colleagues compared four distinct models of 
Option B+ delivery in the South East Zone of Malawi, to determine which was associated 
with the best retention outcomes. These “models of care” were categorized as follows: 
facilities where newly identified HIV-positive women initiate and continue ART within 
antenatal care until delivery (Model A, n=75), facilities where newly identified HIV-positive 
women receive their first does of ART at the antenatal clinic but are then referred to the 
adult ART services for long-term care (Model B, n=38), facilities where newly identified 
HIV-positive women are referred from ART clinic for initiation and follow-up of ART 
(Model C, n=18), and facilities serving as referral sites, without antenatal services (Model D, 
n=9). Compared to Model B, facilities based on Model C was more than five times more 
likely to have retention rates of >92% (adjusted OR: 5.4, 95%CI: 1.2–28.0). Model A 
(adjusted OR: 3.0, 95%CI: 0.7–12) and Model D (adjusted OR: 9.1, 95%CI: 0.9–84) also 
appeared promising, though comparisons did not reach statistical significance [71**]. 
Although the authors note important limitations with this analysis – including geographic 
focus on a single region of Malawi, a relatively small number of facilities for the extensive 
multivariable analysis, and the potential selection bias for Models C and D because of a lack 
of linkage data – this nevertheless provides important insights into how service delivery 
models may influence PMTCT program performance.
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The specific interventions proposed for improving retention in Option B+ largely mirror 
those described for the general HIV treatment. A systematic review conducted by 
Govindasamy and colleagues demonstrated encouraging early findings for a number of 
promising interventions; however, the majority of published studies relied on data from 
observational cohorts and the overall evidence base was judged to be low [72]. Results from 
numerous ongoing trials – to be completed in the coming years – is expected to improve our 
understanding of these strategies applied to the context of Option B+ [73, 74].
Linking HIV-infected infants to long-term care
Initiation of ART in HIV-infected children within the first 12 weeks of life reduces mortality 
and HIV progression by 75% [75]. Universal HIV treatment is now recommended for HIV-
infected children under five years of age [2], but less than one-quarter of HIV-infected 
children ever start [4]. A major barrier has been the timely HIV screening through early 
infant diagnosis (EID) programs and, for those who are diagnosed with HIV, linkages to 
long-term pediatric care.
Despite increased investments in health infrastructure, EID testing among HIV-exposed 
infants remains low in sub-Saharan Africa. The technology needed to accurately diagnose 
newborns (i.e., HIV DNA PCR) is technically complex and limited mostly to reference 
laboratories. Where it does exist, the time from sample collection to results reporting can be 
lengthy [76]. A recent chart review in rural Zambia showed that the median time from 
specimen collection to results reporting was 92 days (IQR: 84, 145) [77]. In Uganda, length 
of turnaround time, HIV testing point, and child age at sample collection further influenced 
receipt of infant HIV result [78]. Several approaches have been undertaken to increase EID 
testing and improve results reporting. Expanding services to different venue types has 
helped to increase access to HIV-exposed infants of differing demographic and clinical 
characteristics [79]. In Malawi, for example, EID testing at immunization points provided 
access to younger HIV-exposed children, higher uptake of HIV testing, and better linkages 
to subsequent care when compared to traditional “under-5” clinics [80]. Seidenberg and 
colleagues used a mobile phone-based system to transmit EID test results from a central 
laboratory to health facilities. Over a 19-month observation window, the intervention 
reduced the time of results reporting from 44 days to 27 days [81]. Point-of-care 
technologies hold great promise in this arena [82, 83], but trials of their effective field 
implementation are still ongoing.
Infant HIV testing provides an important entry point for pediatric HIV care. In order to avert 
the clinical complications of HIV infection, however, timely linkage to and retention in 
clinical services are paramount. A number of studies have characterized the magnitude of 
this problem. A meta-analysis performed by Sibanda, et al. found that one-third of newborn 
infants was LTFU by 3 months following delivery. In a subset of five eligible studies, 46% 
of children were lost following infant HIV testing [84]. In South Africa's Western Cape, a 
retrospective analysis of laboratory data showed a steady increase in successful linkages to 
care from 2005 to 2010; however, the peak of 71% (reported in 2010) remains modest and 
demonstrates significant room for improvement [85]. At present, there have been few 
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intervention studies targeting these critical steps along the continuum of care; as such, the 
evidence base for effective program implementation remains relatively sparse.
New directions in PMTCT implementation research
We provide a survey of new research conducted within the field of PMTCT. Although each 
prong faces unique challenges, we observed numerous cross-cutting clinical and public 
health themes, each representing an opportunity for future work. Health service delivery 
must be optimized in ways that improve access to populations in need and increase retention 
once they are engaged in care. Commonly evaluated approaches have incorporated human 
resource (e.g., lay workers) and technology-based (e.g., mobile phone reminders) 
components; while these have shown to be effective in a number of settings, their 
incorporation into broader structural approaches appear highly promising. Active linkage 
strategies between health services – including integration where possible – are urgently 
needed. Appropriate dissemination and engagement among stakeholders can help to ensure 
that lessons learned from addressing one prong of PMTCT can be appropriately considered, 
adapted, and implemented for others.
To provide ongoing safety and effectiveness data, there is need for ongoing clinical 
surveillance within newly implemented health services. For example, recent work by Scarsi 
and colleagues suggested higher rates of contraceptive failure with efavirenz-based 
regimens, possibly due to pharmacokinetic interactions [86]. Early results from the multi-
center IMPAACT PROMISE study demonstrated higher rates of preterm birth and low 
birthweight infants among women using three-drug combination regimens during 
pregnancy, compared to those on short-course zidovudine and intrapartum nevirapine [87]. 
In both cases, population-level data would greatly enhance our understanding about the “real 
world” impact of such interventions, while providing the framework to evaluate new 
interventions developed to address them.
The design of new implementation strategies must consider not only the target populations, 
but also the context in which they reside. The case of female-initiated pre-exposure 
prophylaxis for HIV prevention is illustrative. These interventions – either administered 
orally or applied vaginally – were developed to engage women in settings where social and 
cultural norms may limit individual medical decision-making. After a series of negative 
randomized trials [88–90], however, it appears that aspects of study context (e.g., 
acceptability, patient preferences) were inadequately addressed [91*]. This may have led to 
poor adherence and a possible confounding of the intervention's biological effect. Similarly, 
several studies have reported significant proportions of women who refuse PMTCT services 
outright, or silently default from care, when not fully prepared to initiate lifelong ART 
during pregnancy. Resource-appropriate tools could be used to assess ART readiness and 
appropriately triage women to different intensities of provider and peer support in the 
critical window immediately following treatment initiation. Finally, when context is well 
characterized and understood, even simple interventions can result in significant impact. In a 
randomized trial in Malawi, for example, Nyondo and colleagues showed that a basic 
invitation card directed at partners increased levels of male involvement at later antenatal 
and PMTCT visits [92].
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We also advocate for better integration of implementation science principles into ongoing 
PMTCT research. While the evaluation of program strategies has been common in PMTCT 
clinical and epidemiologic studies, it is only recently that HIV researchers have engaged 
implementation scientists to better understand the discipline. This is reflected in the diversity 
of projects included in this review. Although most of our referenced studies would be 
loosely termed “implementation research” within the HIV scientific community, central 
tenets of implementation research were often poorly articulated or missing altogether. For 
example, context (i.e., components of the social, cultural, economic, political, legal, and 
physical environment in which implementation took place) features prominently in the early 
design of implementation strategies, since interventions must be adapted to the setting in 
which they are carried out. Description of key contextual features is important to 
understanding why interventions may or may not work in a given setting; if shown to be 
effective, these characteristics may also help others looking to adapt the intervention to their 
individual setting [93]. Fidelity – the extent to which program implementation meets the 
original expectation of its designers [94] – should also be routinely measured in 
implementation studies. Without this information, it may be difficult to differentiate between 
ineffective interventions and otherwise promising strategies that have not been fully 
implemented (also known as a “Type III” error [95]). Structured reporting of 
implementation strategies, similar to CONSORT statement for clinical research, is needed 
[96]. Such standardization, could greatly improve the quality of implementation research 
literature while ensuring that complex strategies are adaptable and scalable in other global 
settings.
Conclusion
Significant investments in PMTCT implementation research have led to new and important 
advancements in the field. Nevertheless, there remain many unanswered questions in the 
realm of implementation that must be urgently addressed. Those conducting such studies 
should incorporate implementation research principles and frameworks to inform the 
development of context-relevant PMTCT strategies [97]. Finally, it is not enough to have the 
goal of effective implementation without addressing the sustainability of evidence-based 
PMTCT interventions in real world settings [98]. By considering these factors holistically, 
we will move more rapidly towards our ultimate goal of eliminating pediatric HIV and 
improving the lives of mothers and infants through the implementation of effective, well-
designed public health programs.
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